Harmony Biosciences (HRMY) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Septerna (SEPN) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 51.1% versus a loss of 5.0%. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.84 billion), about 1.0 times the size, while Septerna is growing revenue faster (+4174.5% vs +21.5%). Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus -106.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | SEPN |
|---|---|---|
| Share price | $32.59 | $38.61 |
| Market cap | $1.91B | $1.84B |
| 1-day change | -1.18% | -1.51% |
| YTD return | -12.91% | +38.49% |
| 1-year return | -5.01% | +51.06% |
| 5-year return | -13.21% | — |
| P/E ratio (TTM) | 10.79 | — |
| Forward P/E | 5.37 | — |
| EPS (TTM) | $3.02 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | $45.95M |
| Revenue growth (YoY) | +21.51% | +4174.51% |
| Net income (latest FY) | $158.69M | $-48.88M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | -148.63% |
| Net margin | 18.27% | -106.37% |
| 52-week high | $43.49 | $53.34 |
| 52-week low | $25.90 | $22.78 |
| Distance from 52-week high | -25.06% | -27.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +47.53% | +53.38% |
| Average volume | 1.01M | 383.96K |
| Shares outstanding | 58.72M | 47.55M |
| Employees | 293 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed HRMY by 56.1 percentage points over the past year.
- Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +21.51%).
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees
HRMY vs SEPN FAQ
Which is bigger, Harmony Biosciences or Septerna?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.84B for Septerna (SEPN).
Which stock has performed better over the past year, HRMY or SEPN?
SEPN returned +51.06% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.